Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01237678 · ClinicalTrials.gov registry record · Phase 1
A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer
A Phase 1 study, sponsored by ImmunoGen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 181
- Enrollment target
NCT01237678 is a Phase 1 study that was terminated before completion, run by ImmunoGen. The registered enrollment target is 181 participants.
The verdict
NCT01237678, a Phase 1 study, was terminated before completion, sponsored by ImmunoGen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 181 participants
- Enrollment target
Study Summary
The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
Interventions
- DRUG IMGN901
- DRUG Carboplatin and Etoposide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 181 participants |
| Start Date | 2010-11 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01237678
The ClinicalTrials.gov registry entry for NCT01237678 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 181 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunoGen, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IMGN901 is the first listed.
NCT01237678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01237678 about?
NCT01237678 is a clinical study titled "A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer". The purpose of this study is to test safety and efficacy of this combination treatment (IMGN901, carboplatin and etoposide) in patients with solid tumors and extensive stage small cell lung cancer.
What is the current status of trial NCT01237678?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 181 participants. The study started on 2010-11. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01237678?
The interventions under investigation include: IMGN901 (DRUG), Carboplatin and Etoposide (DRUG).
Who is sponsoring clinical trial NCT01237678?
This trial is sponsored by ImmunoGen, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.